Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sample
Abstract Cognitive impairment occurs at higher rates in individuals at clinical high risk (CHR) for psychosis relative to healthy peers, and it contributes unique variance to multivariate prediction models of transition to psychosis. Such impairment is considered a core biomarker of schizophrenia. T...
Saved in:
Similar Items
-
Computational modelling reveals neurobiological contributions to static and dynamic functional connectivity patterns
by: Linnea Hoheisel, et al.
Published: (2025-07-01) -
Modelling the impact of environmental and social determinants on mental health using generative agents
by: Joseph Kambeitz, et al.
Published: (2025-01-01) -
An Observational Constraint for Future Greenland Rain in a Warmer Atmosphere
by: M. Thompson‐Munson, et al.
Published: (2025-03-01) -
Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia Program
by: Jean Addington, et al.
Published: (2025-04-01) -
Mapping hippocampal glutamate in healthy aging with in vivo glutamate-weighted CEST (GluCEST) imaging
by: Maggie K. Pecsok, et al.
Published: (2025-01-01)